Company Profile
JCR Pharmaceuticals provides the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan.
It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature. Its portfolio also includes IZCARGO to treat Mucopolysaccharidosis type II, and Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease
TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. Additionally, it sells, imports, and exports medical devices; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies
A. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. Founded in 1975, the company is based in Ashiya, Japan.